BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8580834)

  • 21. Prognostic factors in primary gastric lymphoma.
    Medina-Franco H; Germes SS; Maldonado CL
    Ann Surg Oncol; 2007 Aug; 14(8):2239-45. PubMed ID: 17546474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia.
    Itälä M; Pelliniemi TT; Remes K
    Br J Haematol; 1996 Jul; 94(1):129-32. PubMed ID: 8757522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
    Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
    Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
    Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
    Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
    Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
    Suzuki K; Terui Y; Yokoyama M; Ueda K; Nishimura N; Mishima Y; Sakajiri S; Tsuyama N; Takeuchi K; Hatake K
    Leuk Lymphoma; 2013 Nov; 54(11):2412-7. PubMed ID: 23488601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.
    Kaito S; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y; Hishima T; Maeda Y
    Int J Hematol; 2018 Apr; 107(4):451-459. PubMed ID: 29103138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma.
    Yoo C; Yoon DH; Jo JC; Yoon S; Kim S; Lee BJ; Huh J; Lee SW; Suh C
    Ann Hematol; 2014 Jun; 93(6):995-1000. PubMed ID: 24441948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
    Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
    Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
    Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
    Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
    Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
    Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
    Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
    Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma.
    Simonsson B; Brenning G; Källander C; Ahre A
    Eur J Clin Invest; 1987 Aug; 17(4):336-9. PubMed ID: 3117570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
    Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Acta Haematol; 2015; 133(1):10-7. PubMed ID: 24969101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma.
    Chung KM; Chang ST; Huang WT; Lu CL; Wu HC; Hwang WS; Chang KY; Chuang SS
    J Formos Med Assoc; 2013 Jul; 112(7):382-9. PubMed ID: 23927977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.